Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.50 +1.13%

+$0.32 today

Market cap
$141.11M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.31M

Average 0.28M

STRO Interest Expense

Cost of servicing the company's debt during the period.

Sutro Biopharma, Inc.NASDAQ: STRO

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense dips below year-ago levels

Q1 FY2026 interest expense of $9.47M fell 11.0% year over year, behind the +9.8% change in trailing-twelve-month interest expense. Sequentially, it fell 8.3% from the prior quarter. Over 3 fiscal years it compounded at +125.2% a year.

Context

  • Interest expense amounted to 37.3% of revenue in FY2025, down 12.8 pp from a year earlier.
  • Interest expense increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -11.0% toward the trailing-twelve-month pace of +9.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.47M-8.3% QoQ
Last fiscal yearDec 2025
$38.21M+23.0% YoY
LTMMar 2026
$39.85M+9.8% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.0%——
1 year+23.0%——
3-year CAGR+125.2%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
38.21M USD
Year-over-year change
+23.0%
4-year CAGR
+86.8%

Interest Expense vs competitors

How STRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +9.8% is the 2nd highest of 5, against a peer median of -29.8%.
  • Interest expense amounts to 40.0% of revenue for STRO, versus a peer median of 1.5%.
STRO Competitors
Interest Expense for STRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$39.85M USD+9.8%+125.2%40.0%
PLRXPliant Therapeutics, Inc.LTM Mar 2026$1.76M USD-47.9%+47.9%—
DTILPrecision BioSciences, Inc.LTM Mar 2026$1.38M USD-11.7%+8.6%3.1%
IFRXInflaRx N.V.LTM Mar 2026€48.66K EUR+115.0%-5.9%165.9%
STTKShattuck Labs, Inc.LTM Mar 2026$0 USD——0.0%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$0 USD———
CNTBConnect Biopharma Holdings LimitedFY2025$0 USD——0.0%
KLRSKalaris Therapeutics IncLTM Mar 2026$0 USD-100.0%+83.1%—
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$0 USD———
Peer median (excluding STRO) —-29.8%+28.2%1.5%

Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue61.88M67.77M153.73M62.04M102.48M
Cost of Revenue9.77M8.29M6.82M7.22M7.32M
Gross Profit52.11M59.48M146.92M54.83M95.16M
Gross Margin84.2%87.8%95.6%88.4%92.9%
Research & Development104.4M137.17M180.43M252.04M166.42M
Selling, General & Admin56M59.54M62.58M48.45M41.02M
Operating Expenses150.63M188.43M236.19M293.28M200.11M
Depreciation & Amortization4.84M8.29M6.82M7.22M7.32M
EBITDA(97.56M)(105.07M)(67.92M)(180.45M)(145.65M)
EBITDA Margin-157.7%-155.0%-44.2%-290.9%-142.1%
Operating Income(98.52M)(128.94M)(89.28M)(238.45M)(104.95M)
Operating Margin-159.2%-190.3%-58.1%-384.3%-102.4%
Interest Income577K3.46M14.51M44.43M9.25M
Interest Expense3.14M3.35M23.75M31.07M38.21M
Other Income / Expenses(7.01M)12.24M677K13.36M(86.23M)
Income Before Tax(105.54M)(116.7M)(88.6M)(225.1M)(191.18M)
Pre-Tax Margin-170.6%-172.2%-57.6%-362.8%-186.5%
Income Tax Expense02.5M18.19M2.36M(93K)
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Net Margin-170.6%-175.9%-69.5%-366.6%-186.5%
EPS (Basic)(22.90)(23.50)(17.80)(29.60)(22.49)
EPS (Diluted)(22.90)(23.50)(17.80)(29.60)(22.49)
Weighted Avg Shares4.61M5.07M6.02M7.68M8.5M
Weighted Avg Shares (Diluted)4.61M5.07M6.02M7.68M8.5M

Sutro Biopharma, Inc.

NASDAQ:STRO

Intrinsic Alpha fair value

Locked

Current Price

$8.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.